Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has been given an average recommendation of “Moderate Buy” by the nine research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, four have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $90.6667.

TARS has been the subject of a number of research reports. The Goldman Sachs Group reiterated a “neutral” rating and set a $68.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Lifesci Capital upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. Wall Street Zen cut Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Oppenheimer initiated coverage on Tarsus Pharmaceuticals in a report on Friday, April 24th. They set an “outperform” rating and a $98.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Tuesday, April 21st.

Tarsus Pharmaceuticals Stock Down 0.8%

TARS opened at $58.93 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.71. The stock has a market capitalization of $2.54 billion, a price-to-earnings ratio of -51.69 and a beta of 0.49. The business has a 50-day moving average of $65.10 and a two-hundred day moving average of $70.94. Tarsus Pharmaceuticals has a 12 month low of $38.51 and a 12 month high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The business had revenue of $162.05 million during the quarter, compared to analysts’ expectations of $149.60 million. On average, research analysts expect that Tarsus Pharmaceuticals will post -0.59 earnings per share for the current year.

Insider Buying and Selling

In related news, General Counsel Bryan Wahl sold 4,231 shares of the business’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $283,477.00. Following the transaction, the general counsel directly owned 63,959 shares of the company’s stock, valued at approximately $4,285,253. The trade was a 6.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Dianne C. Whitfield sold 4,174 shares of the business’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $279,658.00. Following the transaction, the insider directly owned 35,028 shares in the company, valued at $2,346,876. This trade represents a 10.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 79,391 shares of company stock valued at $5,432,035. Insiders own 9.64% of the company’s stock.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Rockefeller Capital Management L.P. lifted its position in Tarsus Pharmaceuticals by 15.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after acquiring an additional 172 shares in the last quarter. Parallel Advisors LLC lifted its position in Tarsus Pharmaceuticals by 139.2% during the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock worth $35,000 after acquiring an additional 291 shares in the last quarter. State of Wisconsin Investment Board lifted its position in Tarsus Pharmaceuticals by 1.1% during the 4th quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock worth $2,613,000 after acquiring an additional 332 shares in the last quarter. Federated Hermes Inc. lifted its position in Tarsus Pharmaceuticals by 0.6% during the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock worth $2,229,000 after acquiring an additional 339 shares in the last quarter. Finally, Valeo Financial Advisors LLC lifted its position in Tarsus Pharmaceuticals by 11.1% during the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock worth $321,000 after acquiring an additional 392 shares in the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.